Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8165MR)

This product GTTS-WQ8165MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF1A gene. The antibody can be applied in Dry eye (DE) syndrome research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001065.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7132
UniProt ID P19438.1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ8165MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2327MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ2942MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ2338MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ10077MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ818MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ8904MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ7499MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ10108MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LA480
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW